CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:H2AFY2 suppresses exhaustion and enhances antitumor activity of CAR-T cells through transcriptional and epigenetic modifications.
H2AFY2 suppresses exhaustion and enhances antitumor activity of CAR-T cells through transcriptional and epigenetic modifications.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体(CAR)-T细胞耗竭是持续抗肿瘤疗效的关键障碍。通过对淋巴瘤患者CAR-T 细胞的转录组分析,我们鉴定出组蛋白变体macroH2A2(H2AFY2)是T细胞耗竭的关键调控因子——这一发现在多种肿瘤模型中均得到一致观察。在小鼠中,T细胞特异性敲除H2afy2通过激活核因子κB通路并增加Rela基因座的染色质可及性,促进抑制性受体的表达,这一点已通过单细胞RNA测序和转座酶可及性染色质测序得以证实。CD8+ T细胞中H2AFY2过表达诱导显著的表观遗传重塑,其特征为H3K27me3富集增加。在机制上,Rela基因座的H3K27me3富集抑制p65介导的转录激活,导致耗竭相关转录因子TOX下调,从而改善T细胞耗竭。
此外,过表达H2AFY2的CAR-T 细胞维持较低水平的抑制性受体并抑制肿瘤复发。总体而言,这些结果界定了一条表观遗传通路,H2AFY2通过该通路对抗T细胞耗竭,并支持H2AFY2工程化CAR-T 细胞跨肿瘤类型的治疗潜力。
Chimeric antigen receptor (CAR)-T cell exhaustion constitutes a critical barrier to sustained antitumor efficacy. Through transcriptomic analysis of CAR-T cells from patients with lymphoma, we identified the histone variant macroH2A2 (H2AFY2) as a critical regulator of T cell exhaustion-a finding consistently observed across multiple tumor models.
In mice, T cell-specific knockout of H2afy2 promots the expression of inhibitory receptors by activating the nuclear factor kappa-B pathway and increasing chromatin accessibility at the Rela locus, as demonstrated by single-cell RNA-sequencing and assay for transposase-accessible chromatin sequencing. H2AFY2 overexpression in CD8+ T cells induces prominent epigenetic remodeling, characterized by increased H3K27me3 enrichment.
Mechanistically, H3K27me3 enrichment at the Rela locus suppresses p65-mediated transcriptional activation, leading to downregulation of the exhaustion-associated transcription factor TOX and consequent amelioration of T cell exhaustion.
Furthermore, H2AFY2-overexpressing CAR-T cells sustain lower levels of inhibitory receptors and suppressed tumor recurrence. Collectively, these results define an epigenetic pathway through which H2AFY2 counteracts T cell exhaustion and support the therapeutic potential of H2AFY2-engineered CAR-T cells across tumor types.
MEMBER ACCOUNT
登录成功会直接打开下一页。